BPC-157 is one of several peptide therapies that may help support these goals as part of a personalized treatment plan
Later in 2022, the FDA granted tirzepetide fast track designation for overweight and obesity in adults.6 To date, tirzepetide hasnt been FDA approved for weight loss (see table Current FDA-Approved Mono and Dual Agonists for details about weight management medications)
While these observational data cannot definitively establish causality and may be subject to residual confounding despite sophisticated analytical approaches, the consistency of findings across multiple large, geographically diverse cohorts using different methodologies substantially strengthens confidence in the hepatoprotective benefits of GLP-1-based therapies
Exenatide has a relatively short half-life, (6090 min in humans, Kolterman et al., 2005) and is recommended for twice-daily administration
Finally, to begin to understand how GLP-1(2836) achieves its effects on intracellular ATP, we conducted an unbiased proteomic analysis of heart proteins capable of binding a biotinylated (but still functional) GLP-1(2836)